Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adverse reactions to levamisole.

J Symoens, E Veys, M Mielants

    Cancer Treatment Reports
    |November 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Levamisole can cause agranulocytosis and skin rash, primarily in rheumatoid arthritis patients. These adverse reactions are reversible, and the drug

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Voiding camp: A successful and unique bladder rehabilitation program for children with urinary incontinence.

    Journal of pediatric urology·2024
    Same author

    Sigmoid Resection with Primary Anastomosis for Uncomplicated Giant Colonic Diverticulum : a Report of two Cases.

    Acta chirurgica Belgica·2015
    Same author

    Tailgut cyst. A case report.

    Acta chirurgica Belgica·2011
    Same author

    Vascular Protection by Ketanserin, a 5-HT(2) Serotonergic Receptor Antagonist?

    Platelets·2010
    Same author

    X linked agammaglobulinaemia and rheumatoid arthritis.

    Annals of the rheumatic diseases·2004
    Same author

    Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

    Annals of the rheumatic diseases·2004
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Pharmacology
    • Immunology
    • Rheumatology

    Background:

    • Levamisole is an immunomodulatory drug with a history of use in various conditions.
    • Adverse reactions to levamisole have been reported, necessitating a detailed analysis of their incidence and characteristics.

    Purpose of the Study:

    • To analyze the adverse reactions reported for levamisole.
    • To characterize significant adverse events like agranulocytosis, skin rash, and febrile illness.
    • To assess the safety profile of levamisole, particularly regarding renal, liver, and hematological toxicity.

    Main Methods:

    • Analysis of 267 adverse reaction reports for levamisole.
    • Detailed investigation of blood dyscrasia cases using a questionnaire.
    • Characterization of agranulocytosis, thrombocytopenia, and leukopenia.

    Related Experiment Videos

    Main Results:

    • Significant adverse reactions include agranulocytosis, skin rash, and febrile illness, predominantly in rheumatoid arthritis patients.
    • Agranulocytosis is reversible upon treatment discontinuation and not associated with bone marrow damage.
    • Levamisole did not demonstrate significant renal or liver toxicity.

    Conclusions:

    • Levamisole's benefits outweigh its risks when used under medical supervision for approved indications.
    • Close monitoring is essential to manage potential adverse reactions, particularly agranulocytosis in susceptible populations.
    • Levamisole can be considered a viable treatment option when its efficacy is established and risks are managed.